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Adipose tissue is an active endocrine organ that secretes various humoral factors (adipokines), and its shift to production of
proinflammatory cytokines in obesity likely contributes to the low-level systemic inflammation that may be present in metabolic
syndrome-associated chronic pathologies such as atherosclerosis. Leptin is one of the most important hormones secreted by
adipocytes, with a variety of physiological roles related to the control of metabolism and energy homeostasis. One of these
functions is the connection between nutritional status and immune competence. The adipocyte-derived hormone leptin has been
shown to regulate the immune response, innate and adaptive response, both in normal and pathological conditions. The role of
leptin in regulating immune response has been assessed in vitro as well as in clinical studies. It has been shown that conditions of
reduced leptin production are associated with increased infection susceptibility. Conversely, immune-mediated disorders such as
autoimmune diseases are associated with increased secretion of leptin and production of proinflammatory pathogenic cytokines.
Thus, leptin is a mediator of the inflammatory response.
1. Introduction
White adipose tissue plays a very important role in the
energetic balance of mammals. This tissue is specialized in
storing lipids and supplying fuel to the whole body whenever
it is necessary. In order to face energetic requirements,
adipocytes regulate fatty acid mobilization in response to
catabolic and anabolic stimuli. However, adipose tissue is
not only a reserve organ; it is also an endocrine organ able
to release hormones, peptides, and cytokines (adipokines)
that aﬀect both the energetic status and the immune
system [1]. Leptin is one of the most important hormones
secreted by adipose tissue [2] and its implication in energetic
homeostasis at central level has been largely described [3].
Rather than a “fasting signal”, leptin is a signal of
starvation, in that a falling serum leptin concentration leads
to neurohumoral and behavioural changes, trying to preserve
energy reserves for vital functions. Thus, during fasting
period and after reduction of body fat mass, there is a
decrease in leptin levels that leads to a reduction in total
energy expenditure to provide enough energy for the func-
tion of vital organs, that is, the brain, the heart, and the liver
[4]. Even though these eﬀects of leptin decrease are aimed
to improve the survival chances under starving conditions,
the fall in leptin levels may lead to immune suppression
[5], in addition to other neuroendocrine alterations aﬀecting
adrenal, thyroid, and sexual/reproductive function [6]. At
least, these alterations observed during fasting parallel the
decrease in circulating leptin levels. In fact, both ob/ob
mice (lacking leptin secretion) and db/db mice (lacking
leptin receptor) are not only obese but they also show the
immune/endocrine deficiencies observed during starvation
[5, 7]. Moreover, it has been recently shown that leptin
withdrawal during 8 days in experimental animals leads
to the same eﬀects regarding central control of endocrine
systems including sexual function [8]. Even in humans, it
has been found that leptin levels are associated with immune
response in malnourished infants, which have low plasma
leptin and impaired immune response [9]. Moreover, leptin
signaling deficiency impairs humoral and cellular immune
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responses. The leptin receptor Ob-Rb is expressed by B and
T lymphocytes, suggesting that leptin regulates directly the B
and T cell responses [10].
The leptin modulation of the immune system is also
mediated by the regulation of hematopoiesis and lym-
phopoiesis [7, 11] Thus, seven days of provision of recom-
binant leptin promoted substantial lymphopoiesis, with a
twofold increase of the numbers of B cells in the marrow
of obese mice while doubling and tripling, respectively, the
numbers of pre-B and immature B cells. Twelve days of sup-
plementation brought these subpopulations to near-normal
proportions. Leptin treatment also facilitated myelopoiesis
such that the marrow of the obese mice contained normal
numbers of monocytes and granulocytes after 7 days [12].
Modulation of the immune system by leptin is exerted
at the development, proliferation,antiapoptotic, maturation,
and activation levels [13]. In fact, leptin receptors have
been found in neutrophils, monocytes, and lymphocytes,
and the leptin receptor belongs to the family of class I
cytokine receptors. Moreover, leptin activates similar signal-
ing pathways to those engaged by other members of the
family [14]. The overall leptin action in the immune system
is a proinflammatory eﬀect, activating proinflammatory
cells, promoting T-helper 1 responses, and mediating the
production of the other proinflammatory cytokines, such as
tumor necrosis factor-α, interleukin (IL)-2, or IL-6. Leptin
receptor is also upregulated by proinflammatory signals.
In this paper, we will summarize data from literature that
demonstrate the positive regulation of the immune response
by leptin (Figure 1) [14].
2. Leptin Activation of Innate Immunity
The primary amino acid sequence of leptin indicated that
it could belong to the long-chain helical cytokine family
[15], such as IL-2, IL-12, and GH. In fact, leptin receptor
(Ob-R) shows sequence homology to members of class I
cytokine receptor (gp130) superfamily [16] that includes
the receptor for IL-6, leucocyte inhibitory factor (LIF), and
granulocyte colony-stimulating factor (G-CSF). Moreover,
Ob-R has been shown to have the signaling capabilities of IL-
6-type cytokine receptors [16], activating JAK-STAT, PI3K,
and MAPK signaling pathways [14]. In this context, a role
for leptin in the regulation of innate immunity has been
proposed [14, 17].
Consistent with this role of leptin in the mechanisms of
immune response and host defense, circulating leptin levels
are increased upon infectious and inflammatory stimuli such
as LPS, turpentine, and cytokines [18, 19]. On the other
hand, unlike other members of the IL-6 family, it is not clear
that leptin may induce the expression of acute phase proteins,
and contradictory data have been provided [19, 20]. The
role of leptin regulating innate immunity has been previously
reviewed [6].
2.1. Leptin Activation of Monocytes/Macrophages. Studies of
rodents with genetic abnormalities in leptin or leptin recep-
tors revealed obesity-related deficits in macrophage phagocy-
tosis and the expression of proinflammatory cytokines both
in vivo and in vitro, whereas exogenous leptin upregulated
both phagocytosis and the production of cytokines [21].
Besides, phenotypic abnormalities in macrophages from
leptin-deficient, obese mice have been found [22]. More
importantly, leptin deficiency increases susceptibility to
infectious and inflammatory stimuli and is associated with
dysregulation of cytokine production [19]. More specifically,
murine leptin deficiency alters Kupﬀer cell production of
cytokines that regulate the innate immune system. In this
context, leptin levels increase acutely during infection and
inflammation, and may represent a protective component of
the host response to inflammation [23].
Human leptin was found to stimulate proliferation and
activation of human circulating monocytes in vitro, pro-
moting the expression of activation markers: CD69, CD25,
CD38, and CD71, in addition to increasing the expression of
monocytes surface markers, such as HLA-DR, CD11b, and
CD11c [24]. Besides, leptin potentiates the stimulatory eﬀect
of LPS or PMA on the proliferation and activation of human
monocytes. Moreover, leptin dose-dependently stimulates
the production of proinflammatory cytokines by monocytes,
that is, TNF-α and IL-6 [25] and enhances CC-chemokine
ligand expression in cultured murine macrophage, through
activation of a JAK2-STAT3 pathway [25]. The presence
of both isoforms of the leptin receptor was also assessed.
Later, it was found that leptin directly induces the secretion
of interleukin 1 receptor antagonist in human monocytes
[26] and upregulates IP-10 (interferon-gamma-inducible
protein) in monocytic cells [27]. Moreover, in human
monocytes it has been shown that leptin increased both
statin-inhibitable free radical and cholesterol productions
in vitro [28]. In addition, it accelerates cholesteryl ester
accumulation in human monocyte-derived macrophages by
increasing ACAT-1 expression via JAK2 and PI3K, thereby
suppressing cholesterol eﬄux [29]. In alveolar macrophages
leptin augments leukotriene synthesis [30].
A possible role of leptin as a trophic factor to prevent
apoptosis has also been found in serum-depleted human
monocytes [31], which is further supporting the role of
leptin as a growth factor for the monocyte. Moreover, leptin
regulates monocyte function as assessed by in vitro experi-
ments measuring free radical production. Thus, leptin was
shown to stimulate the oxidative burst in control monocytes
[32], and binding of leptin at the macrophage cell surface
increases lipoprotein lipase expression through oxidative
stress- and PKC-dependent pathways. In this line, leptin
has been found to increase oxidative stress in macrophages
[33]. Finally, leptin could act as a monocyte/macrophage
chemoattractant inducing in vitro maximal chemotactic
responses at 1 ng/mL [34], mediating the inflammatory
infiltrate [35], and inducing tissue factor expression in
human peripheral blood mononuclear cells [36]. On the
other hand, human leptin seems to downregulate oxidative
burst in previously activated monocytes [32].
Dendritic cells belong more to the same cell lineage
than to monocytes/macrophages and also present leptin
receptors (OBRb) on the cell surface [37]. Thus, leptin has
also been found to increase the production of IL-8, IL-12,
IL-6, and TNF-α, whereas it decreases MIP-1-α production
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Figure 1: Role of leptin activating immune-competent cells.
by dendritic cells. Similar to leptin eﬀect on monocytes,it
may increase the survival of dendritic cells, and it may also
increase the expression of surface molecules, such as CD1a,
CD80, CD83, or CD86. Leptin induces functional and mor-
phological changes in human dendritic cells (DCs), directing
them towards Th1 priming and promoting DC survival
via the PI3K-Akt signaling pathway [38]. The involvement
of leptin signaling in DCs survival and maturation has
been observed in leptin receptor- (Ob-R-) deficient db/db
mice. Db/db mice displayed markedly reduced expression
of costimulatory molecules and a Th2-type cytokine profile,
with poor capacity to stimulate allogenic T cell proliferation.
Consistent with their impaired DCs phenotype and function,
db/db DCs showed significantly downregulated activities of
the PI3K/Akt pathway as well as STAT-3 and IkappaB-alpha.
Moreover, the reduced DCs yielded in db/db bone marrow
culture was attributed to significantly increased apoptosis,
which was associated with dysregulated expression of Bcl-2
family genes [39].
The expression of leptin and leptin receptors has been
demonstrated on mast cells, suggesting paracrine and/or
autocrine immunomodulatory eﬀects of leptin on mast cells
[40].
2.2. Leptin Activation of Neutrophils. Human polymor-
phonuclear neutrophils (PMN) have been found to express
leptin receptor in vitro and in vivo [41, 42]. However,
Zarkesh-Esfahani et al. [43] demonstrated that neutrophils
only express the short form of the leptin receptor, which is
enough to signal inside the cell, enhancing the expression
of CD11b and preventing apoptosis [42, 43]. Leptin delayed
the cleavage of Bid and Bax, the mitochondrial release of
cytochrome c and second mitochondria-derived activator
of caspase, as well as the activation of both caspase-8 and
caspase-3 in these cells [42]. Therefore, leptin seems to
behave as a survival cytokine for PMN, similar to G-CSF.
Leptin promotes neutrophils chemotaxis [19, 44].
In fact, the chemoattractant eﬀect is comparable to
that of well-known formyl-methionyl-leucyl-phenylalanine
(FMLP). Otherwise, when leptin acts as a uremic toxin
it interferes with neutrophil chemotaxis [45] and inhibits
neutrophil migration in response to classical neutrophilic
chemoattractants and leptin is endowed with chemotactic
activity toward neutrophils. The two activities, inhibition
of the cell response to chemokines and stimulation of
neutrophil migration, could be detected at similar concentra-
tions. On the contrary, neutrophils exposed to leptin did not
display detectable [Ca2+]i mobilization, oxidant production,
or beta2-integrin upregulation [46].
Moreover, leptin also has a stimulating eﬀect on
intracellular hydrogen peroxide production in PMN al-
though this eﬀect seems to be mediated by the activation
of monocytes [42]. More specifically, leptin modulates
neutrophil phagocytosis of Klebsiella pneumoniae [47] and
in diabetic patients’ neutrophils, an increase in leptin
serum levels has been correlated with the degree of CD11b
expression [48].
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On eosinophils, leptin could upregulate cell surface
expression of adhesion molecules ICAM-1 and CD18 but
suppress ICAM-3 and L-selectin. Moreover, leptin could also
stimulate the chemokinesis of eosinophils and induce the
release of inflammatory cytokines IL-1beta and IL-6 and
chemokines IL-8, growth-related oncogene-alpha, and MCP-
1 [49].
2.3. Natural Killer (NK) Cells. Human NK cells constitutively
express both long and short forms of Ob receptor. Moreover,
the leptin receptors can signal in NK cells, since leptin
activates STAT3 phosphorylation in NK cells. Moreover,
leptin increases IL-2 and perforin gene expression at the
transcription levels in NK cells. Consistent with this role of
leptin regulating NK cells, db/db mice have been found to
have impaired NK cell function [50, 51].
Leptin actions in NK cells include cell maturation, diﬀer-
entiation, activation, and cytotoxicity [20]. Leptin enhances
both the development and the activation of NK cells [50],
increasing IL-12 and reducing the expression of IL-15 [51].
Besides, leptin mediates the activation of NK cells indirectly
by modulation of IL-1β, IL-6, and TNF-α by monocytes and
macrophages [36].
3. LeptinModulation of
Adaptive Immune Response
The role of leptin in cell-mediated immunity has been
obtained working with ob/ob mice [18]. These mice have a
decreased sensitivity of T cells to activating stimuli. Besides,
these animals show atrophy of lymphoid organs [5–7], with
a decrease in the number of circulating T cells and an
increase in the number of monocytes. Besides, ob/ob mice
have a decrease in the number of TNKCD4+ in the liver
[52]. The ability of leptin preventing thymic atrophia is
due to a direct antiapoptotic eﬀect on T cells [7]. Thus,
leptin treatment increases thymic expression of interleukin-
7, an important soluble thymocyte growth factor produced
by medullary thymic epithelial cells (TECs). The hormone
leptin has an intrathymic role in maintaining healthy thymic
epithelium and promoting thymopoiesis, which is revealed
when thymus homeostasis is perturbed by endotoxemia. In
this case, leptin treatment decreases in vivo apoptosis of
double positive thymocytes and promotes proliferation of
double negative thymocytes [53].
In the thymus, Fyn acts as a tyrosine kinase that
transduces the leptin signal independently of JAK2 activation
and mediates some of the immunomodulatory eﬀects of
leptin in this tissue. The tyrosine kinase, Fyn, is constitutively
associated with the Ob-R in thymic cells. Following a leptin
stimulus, Fyn undergoes an activating tyrosine phosphoryla-
tion and a transient association with IRS1 [54].
Acute deficiency of leptin has a potent eﬀect on the
immune system, which is even higher than that observed
in ob/ob mice (genetic defect). Acute hypoleptinemic mice
show a higher decrease in the total number of thymocytes,
and double number of apoptotic cells than ob/ob mice.
Moreover, the acute deficiency of leptin also causes a decrease
in splenic cellularity, which does not occur in ob/ob mice,
even though they have a smaller spleen than control mice [8].
Both ob/ob and db/db mice show defects in cell-mediated
immune response which lead to impaired reaction of delayed
hypersensibility, suppression of skin allograft rejection, and
inhibition of footpad swelling by recall antigens [6, 55–
57]. In recent studies, leptin enhanced in vivo lymphocyte
proliferation in Siberian hamsters (Phodopus sungorus) and
increased splenocyte proliferation in mice [58] as well as it
increased percentage of T cells, particularly CD4+ Th cells,
in peritoneal fluid of patients with endometriosis [59].
Lord et al. 1998 [5], demonstrated that mouse lympho-
cytes express the long form of leptin receptor, and that leptin
modulates in these cells cytokine production. Besides, leptin
also regulates the number and activation of T lymphocytes.
The proliferative response to leptin in mice seems to be
produced in naive T cells (CD4+CD45RA+), whereas it has
been shown that leptin inhibits proliferation of memory
T cells (CD4+CD45RO+) [5]. Leptin provides a survival
signal in double positive T cells (CD4+CD8+) and simple
positive CD4+CD8− thymocytes during thymic maturation
[7]. In addition, leptin promotes the expression of adhesion
molecules in CD4+ T cells, such as VLA-2 (CD49b) or
ICAM-1 (CD54) [5, 18].
More recently, we have reviewed the role of human leptin
on T cell response [14]. Human leptin alone is not able to
activate human peripheral blood lymphocytes in vitro [23]
even though leptin receptor is present and activated in T
lymphocytes upon leptin stimulation, fully triggering the
intracellular signal transduction, as we have also assessed [60,
61]. However, when T lymphocytes are costimulated with
PHA or concanavalin A (Con A), leptin dose-dependently
enhances the proliferation and activation of cultured T lym-
phocytes, achieving maximal eﬀect at 10 nM concentration
[62]. Thus, leptin increases the expression of early activation
markers such as CD69, as well as the expression of late
activation markers, such as CD25, or CD71 in both CD4+
and CD8+ T lymphocytes in the presence of suboptimal
concentrations of activators such as PHA (2 μg/mL) and
after stimulation with PMA-ionomycin [63]. However, when
maximal concentrations of PHA or Con A are employed,
leptin has no further eﬀect. These eﬀects of leptin on T
lymphocytes are observed even in the absence of monocytes,
suggesting a direct eﬀect of human leptin on circulating T
lymphocytes when they are costimulated [62]. The activation
of T cells induces the expression of the long isoform of
the Ob receptor [63]. The need for costimulation with
mitogens to get the eﬀect of leptin in lymphocytes may be
partly explained by this eﬀect of activation, increasing leptin
receptor expression in T lymphocytes. Besides, these data
suggest that the leptin receptor may be regulated in a similar
way to other cytokine receptors, such as the IL-2 receptor
(CD25).
Human leptin not only modulates the activation and
proliferation of human T lymphocytes but also enhances
cytokine production induced by submaximal concentrations
of PHA [62]. Thus, human leptin enhances the production
of IL-2 and IFN-γ in stimulated T lymphocytes. It had been
previously shown in mice that leptin can enhance cognate
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T cell response, skewing cytokine responses towards a Th1
phenotype in mice [5]. These data are in agreement with the
observation of the leptin eﬀect on anti-CD3 stimulation of T
cells, which increases the production of the proinflammatory
cytokine IFN-γ [64]. The eﬀect of leptin polarizing T cells
towards a Th1 response seems to be mediated by stimulating
the synthesis of IL-2, IL-12, and IFN-gamma and the
inhibition of the production of IL-10 and IL-4 [36, 62].
Th1 polarization has been correlated with hyperleptinemia
in hemodialysis patients [65] and the protection of ob/ob
mice in Th1- as well as in Th2-dependent inflammation is
provided by a decreased expression of the key transcription
factors for Th1 and Th2 polarization, T-bet and GATA-3
in naive ob/ob T cells. In this case, leptin was found to be
necessary in T-helper 1- (Th1-) dependent inflammatory
processes acting as a critical regulator of CD4+ T cell
polarization in vitro and in vivo [66]. These data regarding
leptin modulation of Th1-type cytokine production are in
line with the observed eﬀects of leptin stimulating TNF-α
and IL-6 production by monocytes [24], further suggesting
the possible role of human leptin in the regulation of
the immune system inducing a proinflammatory response.
On peripheral blood mononuclear cells of patients with
ankylosing spondylitis, leptin exerts proinflammatory eﬀect
[67] as well as it enhances the proinflammatory cytokines in
normal colonocytes and in HT29 xenografted tumor colono-
cytes. Colonocyte-derived products after leptin treatment
stimulated perforin and granzyme B expressions in normal
CD8 (+) T cells in vitro [68]. In addition, leptin alone or
in combination with IL-1 enhanced the expression of iNOS
and COX-2 and production of NO, PGE (2), IL-6, and IL-
8. The eﬀects of leptin are mediated through activation of
transcription factor nuclear factor-kappaB (NF-kappaB) and
mitogen-activated protein kinase (MAPK) pathway c-Jun
NH (2)-terminal kinase (JNK).The increased synthesis of
proinflammatory mediators is mediated by nitric oxide (NO)
in human osteoarthritic cartilage [69].
On the other hand, leptin promotes T cell survival
and Jurkat T lymphocytes survival [70] by modulating the
expression of antiapoptotic proteins, such as Bcl-xL in stress-
induced apoptosis [71]. This trophic eﬀect of leptin on T
cell is consistent with the reduction in lymphocyte numbers
observed in fasted mice, that might be explained by the acute
decrease in leptin levels [7, 19]. The role of leptin modulating
T cell function in humans has been finally defined by clinical
studies in specific and rare cases of patients with monogenic
obesity. In human obesity due to congenital leptin deficiency,
there is a T cell hyporesponsiveness (in addition to the
expected neuroendocrine/metabolic dysfunction), and not
only leptin treatment in these patients is an eﬀective lowering
body weight but it can also revert T cell response to mitogen
activation in vitro [72]. In addition, leptin has been necessary
in nonagenarians (≥90 years old) to maintain functional
naive CD8 T cells and a healthy immune system [73].
The leptin receptor is highly expressed on the cell
surface of Tregs. Leptin can act as a negative signal for
the proliferation of human Foxp3 (+) CD4 (+) CD25 (+)
regulatory T (T(reg)) cells. In vitro, neutralization with
leptin monoclonal antibody (mAb), during anti-CD3 and
anti-CD28 stimulation, resulted in T(reg) cell proliferation,
which was interleukin-2 (IL-2) dependent. Together with the
finding of enhanced proliferation of T(reg) cells observed
in leptin- and ObR-deficient mice, these results suggest
a potential for therapeutic interventions in immune and
autoimmune diseases [74].
4. Conclusions
In conclusion, leptin plays a role in the activation of the
immune system, and it is a mediator of inflammation. In this
context, leptin may be one of the mediators responsible for
the low-level systemic inflammation that may be present in
metabolic syndrome-associated chronic pathologies such as
atherosclerosis, which is associated with obesity, especially
central obesity. Therefore, leptin may be considered as
a therapeutic target in some clinical situations, such as
proinflammatory states or autoimmune diseases, to control
an excess of immune response, as well as in other clinical
situations, such as starving, to control an excess of exercise,
or immune deficiencies, to improve the impaired immune
response. That is why the investigation of the role of leptin in
the regulation of the immune response remains a challenge
for the future.
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